Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 7,429 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Digestive System Neoplasms Clear all

Conditions: Colorectal Cancer
Interventions: Mailed FIT Outreach, Standardized navigation; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 50 Years to 75 Years
Enrollment: 55,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Breast Cancer, Colon Cancer, Neuropathy
Interventions: topical menthol, placebo lotion; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: BLYG8824A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Duarte, California • Nashville, Tennessee

Conditions: Metastatic Cancer Pancreas
Interventions: PF-03084014, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 5
States / cities: Aurora, Colorado • Rochester, New York

Conditions: Hepatocellular Carcinoma
Interventions: Nofazinlimab (CS1003)+Lenvatinib, Nofazinlimab (CS1003) Placebo+Lenvatinib; Drug
Lead sponsor: CStone Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Coronado, California • Rialto, California • Baltimore, Maryland + 2 more

Conditions: Malignant Digestive System Neoplasm, Nausea and Vomiting
Interventions: Aprepitant, Dexamethasone, Dolasetron Mesylate, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hepatocellular Carcinoma
Interventions: Percutaneous Local Ablation, Hypofractionated Image Guided Radiation Therapy; Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Carcinoma, Hepatocellular
Interventions: ADI-PEG 20; Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Colorectal Cancer
Interventions: sunitinib and capecitabine; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Rectal Cancer
Interventions: PET imaging with [18F]-FLT, [18F]-fluorodeoxythymidine; Device · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pancreatic Adenocarcinoma
Interventions: Temsirolimus, Gemcitabine; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
Interventions: FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 508
States / cities: Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more

Conditions: Advanced Cancer, Pancreas Cancer, Pain
Interventions: Celiac Plexus Radiosurgery; Radiation
Lead sponsor: Dr. Yaacov Lawrence; Government
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: New York, New York • Columbus, Ohio

Conditions: Lung Cancers, Gastrointestinal Cancers
Interventions: Priming Survey; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Interventions: Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization; Drug · Combination Product
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Rectal Cancer
Interventions: Cetuximab, 5-fluorouracil, Pelvic irradiation; Drug · Radiation
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 41
States / cities: Tucson, Arizona • Melbourne, Florida • Miami, Florida + 36 more

Conditions: Colorectal Neoplasms, Breast Neoplasms
Interventions: Chi gung: Stay Well, Live Well; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: New York, New York

Conditions: HCC, Liver Cancer
Interventions: MRI and HIDA scan; Radiation
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pancreas Cancer, Metastatic, Pancreas Carcinoma
Interventions: STRONG intervention App, individualized remote dietitian; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions: NKTR-255, Cetuximab; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more

Conditions: Pancreatic Cyst
Interventions: Not listed
Lead sponsor: Translational Genomics Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Newport Beach, California • Atlanta, Georgia

Conditions: Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Interventions: Rituximab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colorectal Carcinoma, Lynch Syndrome
Interventions: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSP, Biospecimen Collection, Endoscopic Biopsy, MVA Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP, Questionnaire Administration; Biological · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Duarte, California • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Solid Tumor
Interventions: Selinexor, Acetaminophen; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 4
States / cities: Tampa, Florida • Detroit, Michigan • New York, New York + 1 more

Search by objective public record fields.

ColoRectal Cancer Screening for Southern California Community Health Centers

Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy

A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

Trial Comparing PLA to HIGRT (PROVE-HCC)

Testing of ADI-PEG in Hepatocellular Carcinoma

Sunitinib and Capecitabine for First Line Colon Cancer

Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Celiac Plexus Radio-Surgery for Pain Management

Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Pre-op Rectal ChemoRad +/- Cetuximab

Increasing Breast and Colorectal Cancer Screening in the Community

A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver

The STRONG Nutrition Support Study for People With Pancreatic Cancer

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Blood and Cystic Fluid From Patients Undergoing Surgery for Worrisome Pancreatic Cysts

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer